Kindred Biosciences (KIN) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KIN Hot Sheet
Join SI Premium – FREE
Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.32), $0.12 better than the analyst estimate of ($0.44).
For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Palomar Holdings Inc. (PLMR) Tops Q3 EPS by 46c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
